Diseases & Longevity · File 15

Acute myocardial infarction. The visible consequence of 30 years of biology that IS modifiable.

MI appears as acute event — minutes, hours — but its biology builds in the cardiometabolic cluster over 20 to 30 years. INTERHEART study (Yusuf et al., Lancet 2004) identified 9 modifiable factors explaining 90% of population risk. That figure defines priority: measure and modulate those factors in the window where they are modifiable — not wait for the event.

Why MI is a trajectory disease, not an accident

The MI occurs as acute event — atherosclerotic plaque ruptures, thrombus occludes a coronary artery, myocardial ischemia, necrosis. But the atherosclerosis culminating in that event builds 20 to 30 years earlier: dyslipidemia with elevated ApoB, sustained HTN, hyperglycemia, vascular inflammaging, endothelial damage, smoking. The event is the visible consequence of a silent trajectory.

INTERHEART (Yusuf et al., Lancet 2004, n=15,152 cases vs 14,820 controls in 52 countries) quantified something decisive: 9 modifiable factors (dyslipidemia, smoking, HTN, diabetes, abdominal obesity, psychosocial stress, diet, exercise, alcohol) explain 90% of population MI risk. That figure leaves no margin: primary prevention works, and the window is decades long.

MI is not an accident. It is the visible consequence of 30 years of biology that could be measured and modulated earlier.
Modifiable factors · INTERHEART

The global weight, in numbers

Quantitative MI data come from INTERHEART, GBD, national registries (NRMI, SWEDEHEART), and meta-analyses. These points sustain clinical priority.

  • 9 factors explain 90%

    INTERHEART · n=30,000

    Dyslipidemia (ApoB/ApoA1), smoking, HTN, diabetes, abdominal obesity, psychosocial stress, diet, exercise, alcohol — explain 90% of population MI risk. Consistent across regions and genders.
    — Yusuf et al., Lancet 2004

  • Global burden

    #1 muerte CV

    Ischemic heart disease (including MI) remains the leading cause of death worldwide — ~9 million deaths per year. Early mortality has decreased in HICs, but global burden persists.
    — GBD 2019; WHO GHE 2020

  • Post-MI mortality

    Recurrencia 5a ~20%

    Hospital MI mortality has significantly decreased in HICs, but 5-year recurrence — MI, stroke, HF, CV death — exceeds 20%. Intensive secondary prevention changes prognosis.
    — SWEDEHEART; AHA 2024 Statistics

  • Elevated ApoB

    Predictor causal directo

    Sniderman 2019 confirmed ApoB is direct causal predictor of coronary events — superior to classical LDL. In the cardiometabolic cluster, small dense particles with elevated ApoB are the longevity target.
    — Sniderman et al., JAMA Cardiol 2019

Chap. 03 · Post-acute event

Impact on quality of life and post-MI trajectory

After the acute event, the post-MI trajectory determines quality of life. Longevity medicine complements secondary prevention with biomarkers and systemic comorbidity.

  • Post-MI heart failure

    ~25% a 5 años

    Up to 25% of patients develop HF in 5 years post-MI — particularly when infarct area is large or acute management was delayed. It's the leading cause of post-MI death and disability.
    — SWEDEHEART; Eur Heart J

  • Post-MI depression

    ~20% pacientes

    Approximately 20% of patients develop clinical depression in the first year post-MI — independent predictor of re-hospitalization, worse adherence, and higher CV mortality. Its management is part of secondary prevention.
    — Lichtman et al., Circulation 2014

  • Return to work and autonomy

    60-70% retorno

    Post-MI return to work varies 60-70% in countries with structured cardiac rehabilitation systems. Functional capacity, SF-36 PCS, and autonomy improve significantly with 8-12 weeks supervised rehabilitation.
    — Anderson L, Cochrane 2016

  • Adherence and discontinuation

    30% abandonan a 1 año

    Approximately 30% of post-MI patients discontinue at least one key drug (statin, antiplatelet, beta-blocker, ACEi) in the first year — solid predictor of recurrence. Structured support changes this number.
    — Kronish et al., Am Heart J 2011

What we don't offer — and what we do

Wellness Care does not manage acute MI. Primary angioplasty, stents, thrombolysis, and coronary ICU management are the interventional cardiologist's and hospital's responsibility. What we do is what the system rarely integrates: structured primary prevention (in patients with cardiometabolic cluster, family history, elevated ApoB) and optimization of post-MI secondary prevention (comorbidities, depression, sarcopenia, adherence, advanced biomarkers).

We evaluate patients with high-risk cardiometabolic profile without prior event, family history of early MI, elevated ApoB never addressed, unmanaged post-MI depression / sarcopenia / cognitive decline, or patients wanting to understand their CV trajectory before symptoms. Intervention is always in coordination with cardiology, not in parallel.

Primary prevention is 90% modifiable. Post-MI secondary prevention is 100% imperative. That is where serious cardiovascular longevity operates.
How we measure it

How MI risk is evaluated
at Wellness Care

9 INTERHEART factors + advanced biomarkers + cardiometabolic cluster + systemic comorbidities. Cardiology coordination always.

Advanced biomarkers

21 specialized panels across 8 clinical categories — biological age, inflammaging, metabolic profile, functional hormonal, microbiota. The quantitative layer.

Explore →

Functional medicine

Shared root causes — mitochondrial dysfunction, inflammaging, neuroendocrine dysregulation — before organ pathology.

Explore →

Bioregulatory medicine

Autonomic regulation, HRV, stress response. The functional trajectory that precedes clinical diagnosis.

Explore →

The Longevity Program

How this assessment integrates into the full program — from initial valuation to individualized protocol design under medical judgment.

Explore →
Featured evidence

Key evidence supporting this approach

Four publications structuring the MI conversation in longevity medicine — INTERHEART, causal ApoB, post-MI depression, cardiac rehabilitation.

«9 factores modificables — dislipidemia, tabaco, HTA, DM, obesidad abdominal, estrés psicosocial, dieta, ejercicio, alcohol — explican el 90% del riesgo poblacional de IAM.»
Lancet · 2004 · n=30,000
Yusuf et al., Lancet 2004
INTERHEART — 52 países
«La depresión clínica post-IAM es predictor independiente de re-hospitalización y mortalidad CV — su abordaje es parte integral de la prevención secundaria.»
Circulation · 2014
Lichtman et al., Circulation 2014
Depresión post-IAM
«La rehabilitación cardíaca estructurada (8-12 semanas) mejora capacidad funcional, calidad de vida y reduce mortalidad CV a largo plazo post-IAM.»
Cochrane · 2016
Anderson L et al., Cochrane 2016
Rehabilitación cardíaca

Frequently asked questions about acute myocardial infarction

The most recurrent questions about MI — the 9 INTERHEART factors, primary and secondary prevention, and how longevity medicine complements the cardiologist.

01

How modifiable is heart attack risk really?

Significantly.

INTERHEART 2004 showed 9 modifiable factors explain 90% of population MI risk.

Mendelian randomization on LDL/ApoB confirms genetically determined reductions proportionally reduce CV risk — direct causal confirmation.

Structured primary prevention has solid long-term demonstrated effect:

· Lifestyle intervention
· Pharmacological when indicated

02

Which biomarkers predict MI before the event?

In longevity medicine we evaluate:

· Advanced lipid profile — ApoB, Lp(a), non-HDL, LDL particles
· Inflammaging — hsCRP, IL-6, fibrinogen
· Metabolic — HbA1c, insulin, HOMA index
· Renal — cystatin C, microalbuminuria
· Hormonal — testosterone, DHEA-S when applicable
· Endothelial function (when available)
· Global CV score (SCORE2 or ASCVD) refined by advanced biomarkers

No single biomarker defines risk — the pattern guides.

03

I had an MI. What does longevity medicine add?

Complements the cardiologist's secondary prevention by addressing what the conventional system rarely integrates:

· Secondary sarcopenia — post-MI mortality predictor
· Post-MI depression — ~20% of patients, worsens prognosis
· Vascular cognitive decline
· Cardiometabolic cluster optimization
· Advanced biomarkers — residual ApoB, Lp(a), hsCRP
· Structured cardiac rehabilitation
· Longitudinal pharmacological adherence

Does not replace the cardiologist — complements with systemic view.

04

Does cardiac rehabilitation really work?

Yes.

Cochrane 2016 review (Anderson L et al.) showed that structured cardiac rehabilitation combines:

· Supervised exercise
· Education
· Risk factor management
· Psychological support

Improves:

· Functional capacity
· Quality of life
· Drug adherence
· Reduces long-term CV mortality

Despite solid evidence, actual participation in cardiac rehabilitation programs is low globally — major implementation gap.

05

When should I consult?

A structured assessment is worthwhile if you have:

· Family history of early MI (<60)
· Cardiometabolic cluster — HTN + dyslipidemia + T2D + obesity
· Active smoking
· ApoB / Lp(a) never measured
· Chronic stress or depression
· Previous MI and want to optimize secondary prevention
· Want to understand your CV trajectory before symptoms

The assessment complements the cardiologist — does not replace them.

30 years of biology before the event

MI is not an accident — it is the visible consequence of 30 years of biology that could be measured and modulated earlier.

Measure the 9 INTERHEART factors, evaluate ApoB and Lp(a), address the cardiometabolic cluster years before the event — and optimize post-MI secondary prevention in coordination with cardiology. That is what's missing in the fragmented model.

Family history, post-MI, or multiple risk factors?

Book a comprehensive cardiovascular assessment

We evaluate the 9 INTERHEART factors, advanced lipid profile (ApoB, Lp(a)), inflammaging (hsCRP), metabolic profile, body composition, CV longevity biomarkers. If you have already had an MI, we complement the cardiologist's secondary prevention with systemic longevity view.

Book comprehensive cardiovascular assessment